Twelve-month results of the ADAPT randomized controlled trial: reproducibility and sustainability of advanced hybrid closed loop therapy outcomes versus conventional therapy in adults with type 1 diabetes
التفاصيل البيبلوغرافية
العنوان:
Twelve-month results of the ADAPT randomized controlled trial: reproducibility and sustainability of advanced hybrid closed loop therapy outcomes versus conventional therapy in adults with type 1 diabetes
Evans, Mark [0000-0001-8122-8987], Apollo - University of Cambridge Repository
بيانات النشر:
Wiley, 2023.
سنة النشر:
2023
الوصف:
In the care of type 1 diabetes, there is growing adoption of hybrid closed loop systems, as they have been shown in clinical trials and real-world use to safely provide favorable glycemic control compared to multiple daily injection and compared to sensor augmented pump therapies1-3. However, access to these technologies is often limited, as a stepwise approach to diabetes technologies is recommended. Hence, people with diabetes requiring intensive insulin therapy must start with multiple daily injection (MDI) therapy and self-monitoring blood glucose (SMBG) or intermittent scanning continuous glucose monitoring (CGM) before progressing to MDI therapy with real-time CGM, eventually moving on to automated insulin delivery (AID) system therapy if necessary4. This can be a lengthy process, exposing people with diabetes to prolonged periods of suboptimal blood glucose levels. Following this stepwise approach, there is evidence to support an improvement in glucose control with the MiniMedTM 780G Advanced Hybrid Closed Loop AID system compared to its predecessors (MiniMedTM 670G system)5 and to sensor-augmented pumps with predictive low glucose management6. However, to support a more direct approach to advanced diabetes management technology, it was of interest to compare the MiniMedTM 780G system to the most prevalent therapy, namely multiple daily injections (MDI) with intermittent scanning continuous glucose monitoring (isCGM)7.
